Overview of Dr. Abdelrahim
Dr. Maen Abdelrahim is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Clear Lake Hospital. He received his medical degree from Texas AM Health Science Center College of Medicine and has been in practice 10 years. He is one of 91 doctors at Houston Methodist Hospital and one of 38 doctors at Houston Methodist Clear Lake Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Texas A&M; Health Science Center College of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2014 - 2025
NC State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Start of enrollment: 2021 Feb 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Neoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma.Nadine Soliman, Ashton A Connor, Ashish Saharia, Sudha Kodali, Ahmed Elaileh
Transplantation Direct. 2025-03-01 - Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression.Samar Semaan, Ashton A Connor, Ashish Saharia, Sudha Kodali, Ahmed Elaileh
Transplantation Proceedings. 2025-03-01 - Sorafenib as Adjuvant Therapy Post-Liver Transplant: A Single-center Experience.Hala Hassanain, Ashton A Connor, Elizabeth W Brombosz, Khush Patel, Ahmed Elaileh
Transplantation Direct. 2025-02-01
Press Mentions
Surgical Options for Cholangiocarcinoma Enhance SurvivalJuly 19th, 2024- Study Finds Daily Aspirin Use Improves Colorectal Cancer OutcomesJuly 19th, 2024
New Recommendation to Start Colorectal Cancer Screenings at Age 45: What to KnowFebruary 4th, 2020- Join now to see all
Grant Support
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
